SGMO News and Press, Sangamo Therapeutics Inc. From 04/27/23

2023-04-27 11:58:03 ET Sangamo Therapeutics, Inc. (SGMO) Q1 2023 Earnings Conference Call April 27, 2023 08:30 A.M. ET Company Participants Louise Wilkie - VP, IR and Corporate Communications Alexander D. Macrae - President and CEO D. Mark McClung - EVP and COO ...

2023-04-27 08:22:53 ET The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Sangamo Therapeutics, Inc. 2023 Q1 - Results - Earnings Call Presentation

2023-04-26 17:53:06 ET For further details see: Sangamo Therapeutics to undergo restructuring; laying off 27% of workforce

Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. Unveiled Nav1.7 target to treat chronic neurop...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023. The Company will hold a conference call at 8:30 a.m. ET on Thursday, A...

2023-04-16 06:30:42 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extrem...

2023-04-13 15:59:42 ET Shares of gene editing companies rose Thursday as Wall Street took notice of the underperforming subsector issuing a series of bullish views despite the recent selloff. Notable gainers include Editas Medicine ( NASDAQ: EDIT ), Sangamo Therapeutics ( SG...

2023-03-23 02:52:15 ET Summary Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfizer will be able to file BLA to the FDA of giroctoc...

2023-03-17 18:11:31 ET Novartis ( NYSE: NVS ) said it is ending an agreement it inked in 2020 with Sangamo Therapeutics ( NASDAQ: SGMO ) to research gene regulation therapies to treat three neurodevelopment disorders. Biogen ( NASDAQ: BIIB ) is also ending ...

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...